Document Detail


PTEN: tumour suppressor, multifunctional growth regulator and more.
MedLine Citation:
PMID:  12928488     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The tumour suppressor gene PTEN is mutated in a wide range of human cancers at a frequency roughly comparable with p53. In addition, germline PTEN mutations are associated with several dominant growth disorders. The molecular and cellular basis of these disorders has been elucidated by detailed in vivo genetic analysis in model organisms, in particular the fruit fly and mouse. Studies in the fly have shown that PTEN's growth regulatory functions are primarily mediated via its lipid phosphatase activity, which specifically reduces the cellular levels of phosphatidylinositol 3,4,5-trisphosphate. This activity antagonizes the effects of activated PI3-kinase in the nutritionally controlled insulin receptor pathway, thereby reducing protein synthesis and restraining cell and organismal growth, while also regulating other biological processes, such as fertility and ageing. Remarkably, this range of functions appears to be conserved in all higher organisms. PTEN also plays a role as a specialized cytoskeletal regulator, which, for example, is involved in directional movement of some migratory cells and may be important in metastasis. Furthermore, conditional knockouts in the mouse have recently revealed functions for PTEN in other processes, such as cell type specification and cardiac muscle contractility. Genetic approaches have therefore revealed a surprising diversity of global and cell type-specific PTEN-regulated functions that appear to be primarily controlled by modulation of a single phosphoinositide. Together with evidence from studies in cell culture that suggests links between PTEN and other growth regulatory genes such as p53, these studies provide new insights into PTEN-linked disorders and are beginning to suggest potential clinical strategies to combat these and other diseases.
Authors:
Deborah C I Goberdhan; Clive Wilson
Related Documents :
1672638 - Activation of cmgf expression is a critical step in avian myeloid leukemogenesis.
23912458 - Identification of rbck1 as a novel regulator of fkbpl: implications for tumor growth an...
23372488 - Renewing the assault on mrna.
22445828 - Gene transcripts in spermatozoa: markers of male infertility.
11039898 - P27kip1-independent cell cycle regulation by myc.
11927338 - Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2003-08-19
Journal Detail:
Title:  Human molecular genetics     Volume:  12 Spec No 2     ISSN:  0964-6906     ISO Abbreviation:  Hum. Mol. Genet.     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-09-23     Completed Date:  2004-06-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9208958     Medline TA:  Hum Mol Genet     Country:  England    
Other Details:
Languages:  eng     Pagination:  R239-48     Citation Subset:  IM    
Affiliation:
Department of Human Anatomy and Genetics, University of Oxford, Oxford, UK. deborah.goberdhan@anat.ox.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Division / genetics*
Cell Movement / genetics
Genes, Tumor Suppressor*
Mutation
Protein Biosynthesis
Tumor Suppressor Protein p53 / physiology
Chemical
Reg. No./Substance:
0/Tumor Suppressor Protein p53

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Towards integrated clinico-genomic models for personalized medicine: combining gene expression signa...
Next Document:  An ultrasensitive Ca2+/calmodulin-dependent protein kinase II-protein phosphatase 1 switch facilitat...